GnRH agonists are claimed to exert major antiproliferative effects that occur in endometrial and ovarian cancer, as well as in primary cell cultures. GnRH antagonists also suppress the growth of carcinoma cells in the endometrium and ovary tissues and confirm that drugs behave similarly to the GnRHR agonists in reproductive tissue tumors. This evidence concerns the gene GNRH1 and ovarian carcinoma.